Coagulopathy triggered autoimmunity: experimental antiphospholipid syndrome in factor V Leiden mice

BMC Medicine

Joab Chapman³  Yehuda Shoenfeld¹  Chaim G Pick⁵  Miri Blank¹  Olga Touloumi²  Tania Ebert⁴  Nikolaos C Grigoriadis²  Aviva Katzav¹ 

[1] Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, affiliated to Sackler Faculty of Medicine, Tel Aviv University, Tel-Hashomer, 2 Sheba Rd, Ramat Gan, 52621, Israel;Department of Neurology, AHEPA University Hospital, Aristotle University of Thessaloniki, St. Kyriakidis 1, Thessaloniki, 54636, Greece;Department of Neurology, Sackler Faculty of Medicine, Tel Aviv University, 55 Haim Levanon St, Ramat Aviv, Tel Aviv, 69978, Israel;Beer Yaakov-Ness Ziona Mental Health Center, 1 Haim Rd, Beer Yaakov, 70350, Israel;Department of Anatomy and Anthropology, Sackler Faculty of Medicine, Tel Aviv University, 55 Haim Levanon St, Ramat Aviv, Tel Aviv, 69978, Israel

关键词: Neurodegeneration;    Cognitive dysfunction;    Hyperactivity;    Autoantibodies;    Experimental antiphospholipid syndrome;    Factor V leiden;    Antiphospholipid syndrome;    Coagulopathy;    Autoimmunity;   

Others  :  857114
DOI  :  10.1186/1741-7015-11-92

 received in 2012-10-18, accepted in 2013-01-31,  发布年份 2013

【 摘 要 】

Background

We investigated interactions between genetically and autoimmune-mediated coagulopathies by inducing experimental antiphospholipid syndrome (eAPS) in mice carrying the factor V Leiden (FVL) mutation.

Methods

eAPS was induced in heterozygous and homozygous FVL transgenic mice (C57BL/6 background) by immunization with β₂-glycoprotein I (β₂-GPI). Autoantibody levels were measured at 1 and 5 months post-immunization. Mice were tested at 4 months post-immunization for behavior and cognitive function in the staircase, elevated plus-maze, and swim T-maze tests. Brains were removed and analyzed by immunohistochemistry for inflammatory markers and neurodegenerative processes.

Results

A single immunization with β₂-GPI induced significantly higher and longer-lasting immune responses, and this was dependent on the number of FVL alleles. At 1 and 5 months post-immunization, levels of antibodies rose from 1.17 ± 0.07 to 1.62 ± 0.17 (optical density units; ODU) in homozygous FVL mice, compared with stable levels of 0.59 ± 0.17 and 0.48 ± 0.16 ODU in heterozygous FVL mice and a drop from 1.62 ± 0.21 to 0.61 ± 0.13 ODU in wild-type mice. Behavioral and cognitive clinical features of eAPS were also correlated with FVL allele load, as assessed by the elevated plus-maze (altered anxiety), staircase (hyperactivity and higher exploration), and swim T-maze (impaired learning) tests. Histological studies identified significant neurodegenerative changes in both grey and white matter in the eAPS-FVL brains. In spite of the potential interaction of two prothrombotic disease states, there were no ischemic lesions seen in this group.

Conclusions

The results indicate that genetically mediated coagulopathies increase the risk of developing coagulation-targeted autoimmune responses, and suggest the importance of antibody-mediated neurodegenerative processes in the brain in APS.

【 授权许可】

   
2013 2013 Katzav et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Rosendorff A, Dorfman DM: Activated protein C resistance and factor V Leiden: a review. Arch Pathol Lab Med 2007, 131:866-871.
• [2]Segers K, Dahlback B, Nicolaes GA: Coagulation factor V and thrombophilia: background and mechanisms. Thromb Haemost 2007, 98:530-542.
• [3]De Stefano V, Chiusolo P, Paciaroni K, Leone G: Epidemiology of factor V Leiden: clinical implications. Semin Thromb Hemost 1998, 24:367-379.
• [4]Rees DC, Cox M, Clegg JB: World distribution of factor V Leiden. Lancet 1995, 346:1133-1134.
• [5]Biggioggero M, Meroni PL: The geoepidemiology of the antiphospholipid antibody syndrome. Autoimmun Rev 2010, 9:A299-A304.
• [6]Diz-Kucukkaya R, Demir K, Yenerel MN, Nalcaci M, Kaymakoglu S, Inanc M: Coexistence of homozygous factor V Leiden mutation and antiphospholipid antibodies in two patients presented with Budd-Chiari syndrome. Haematologia (Budap) 2002, 32:73-77.
• [7]Picillo U, De Lucia D, Palatiello E, Scuotto A, Marcialis MR, Pezzella S, Tirri G: Association of primary antiphospholipid syndrome with inherited activated protein C resistance. J Rheumatol 1998, 25:1232-1234.
• [8]Schutt M, Kluter H, Wiedemann GJ, Richardt G: Coexistence of factor V Leiden and primary antiphospholipid syndrome: a patient with recurrent myocardial infarctions and thrombocytopenia. Z Kardiol 2000, 89:1067-1071.
• [9]Kaiser R, Barton JL, Chang M, Catanese JJ, Li Y, Begovich AB, Criswell LA: Factor V Leiden and thrombosis in patients with systemic lupus erythematosus: a meta-analysis. Genes Immun 2009, 10:495-502.
• [10]Alarcon-Segovia D, Ruiz-Arguelles GJ, Garces-Eisele J, Ruiz-Arguelles A: Inherited activated protein C resistance in a patient with familial primary antiphospholipid syndrome. J Rheumatol 1996, 23:2162-2165.
• [11]Aznar J, Villa P, Espana F, Estelles A, Grancha S, Falco C: Activated protein C resistance phenotype in patients with antiphospholipid antibodies. J Lab Clin Med 1997, 130:202-208.
• [12]Bokarewa MI, Bremme K: Production of phospholipid antibodies in selected thrombophilic women differing in genotype at the 506 site of factor V. Eur J Haematol 1998, 61:21-26.
• [13]Nojima J, Kuratsune H, Suehisa E, Iwatani Y, Kanakura Y: Acquired activated protein C resistance associated with IgG antibodies against beta2-glycoprotein I and prothrombin as a strong risk factor for venous thromboembolism. Clin Chem 2005, 51:545-552.
• [14]Ruiz-Arguelles GJ, Garces-Eisele J, Alarcon-Segovia D, Ruiz-Arguelles A: Activated protein C resistance phenotype and genotype in patients with primary antiphospholipid syndrome. Blood Coagul Fibrinolysis 1996, 7:344-348.
• [15]Viveros ME, Cabiedes J, Reyes E, Cabral AR: Activated protein C resistance and lupus anticoagulant activity induced by plasma and purified monospecific human IgG anti-beta2-glycoprotein-I antibodies. Rev Invest Clin 2005, 57:563-571.
• [16]Katzav A, Pick CG, Korczyn AD, Oest E, Blank M, Shoenfeld Y, Chapman J: Hyperactivity in a mouse model of the antiphospholipid syndrome. Lupus 2001, 10:496-499.
• [17]Shrot S, Katzav A, Korczyn AD, Litvinju Y, Hershenson R, Pick CG, Blank M, Zaech J, Shoenfeld Y, Sirota P, Chapman J: Behavioral and cognitive deficits occur only after prolonged exposure of mice to antiphospholipid antibodies. Lupus 2002, 11:736-743.
• [18]Cui J, Eitzman DT, Westrick RJ, Christie PD, Xu ZJ, Yang AY, Purkayastha AA, Yang TL, Metz AL, Gallagher KP, Tyson JA, Rosenberg RD, Ginsburg D: Spontaneous thrombosis in mice carrying the factor V Leiden mutation. Blood 2000, 96:4222-4226.
• [19]Polz E, Wurm H, Kostner GM: Investigations on beta 2-glycoprotein-I in the rat: isolation from serum and demonstration in lipoprotein density fractions. Int J Biochem 1980, 11:265-270.
• [20]Ball-Rosen C, Primak-Rubinovicz H, Korczyn AD, Wang N, Farchi A, Shavit S, Shoenfeld Y, Chapman J: Identification of histidine-rich glycoprotein, a potential autoantigen, in human and rat brain preparations. Ann N Y Acad Sci 2007, 1109:473-483.
• [21]Bakimer R, Fishman P, Blank M, Sredni B, Djaldetti M, Shoenfeld Y: Induction of primary antiphospholipid syndrome in mice by immunization with a human monoclonal anticardiolipin antibody (H-3). J Clin Invest 1992, 89:1558-1563.
• [22]Paxinos G, Franklin KBJ: The mouse brain in stereotaxic coordinates. San Diego: Academic; 2004.
• [23]Katzav A, Litvinjuk Y, Pick CG, Blank M, Shoenfeld Y, Sirota P, Chapman J: Genetic and immunological factors interact in a mouse model of CNS antiphospholipid syndrome. Behav Brain Res 2006, 169:289-293.
• [24]Katzav A, Shoenfeld Y, Chapman J: The pathogenesis of neural injury in animal models of the antiphospholipid syndrome. Clin Rev Allergy Immunol 2010, 38:196-200.
• [25]Ziporen L, Shoenfeld Y, Levy Y, Korczyn AD: Neurological dysfunction and hyperactive behavior associated with antiphospholipid antibodies. A mouse model. J Clin Invest 1997, 100:613-619.
• [26]Katzav A, Faust-Socher A, Kvapil F, Michaelson DM, Blank M, Pick CG, Shoenfeld Y, Korczyn AD, Chapman J: Antiphospholipid syndrome induction exacerbates a transgenic Alzheimer disease model on a female background. Neurobiol Aging 2011, 32:272-279.
• [27]Tanne D, Katzav A, Beilin O, Grigoriadis NC, Blank M, Pick CG, Landenberg P, Shoenfeld Y, Chapman J: Interaction of inflammation, thrombosis, aspirin and enoxaparin in CNS experimental antiphospholipid syndrome. Neurobiol Dis 2008, 30:56-64.
• [28]Chapman J, Abu-Katash M, Inzelberg R, Yust I, Neufeld MY, Vardinon N, Treves TA, Korczyn AD: Prevalence and clinical features of dementia associated with the antiphospholipid syndrome and circulating anticoagulants. J Neurol Sci 2002, 203–204:81-84.
• [29]Mosek A, Yust I, Treves TA, Vardinon N, Korczyn AD, Chapman J: Dementia and antiphospholipid antibodies. Dement Geriatr Cogn Disord 2000, 11:36-38.
• [30]Lang B, Vincent A: Autoantibodies to ion channels at the neuromuscular junction. Autoimmun Rev 2003, 2:94-100.
• [31]Dalmau J, Rosenfeld MR: Paraneoplastic syndromes of the CNS. Lancet Neurol 2008, 7:327-340.
• [32]Irani SR, Vincent A: Autoimmune encephalitis – new awareness, challenging questions. Discov Med 2011, 11:449-458.
• [33]Shoenfeld Y, Nahum A, Korczyn AD, Dano M, Rabinowitz R, Beilin O, Pick CG, Leider-Trejo L, Kalashnikova L, Blank M, Chapman J: Neuronal-binding antibodies from patients with antiphospholipid syndrome induce cognitive deficits following intrathecal passive transfer. Lupus 2003, 12:436-442.
• [34]Katzav A, Kivity S, Blank M, Shoenfeld Y, Chapman J: Adjuvant immunization induces high levels of pathogenic antiphospholipid antibodies in genetically prone mice: another facet of the ASIA syndrome. Lupus 2012, 21:210-216.
• [35]Katzav A, Faust-Socher A, Kvapil F, Michaelson DM, Blank M, Pick CG, Shoenfeld Y, Korczyn AD, Chapman J: Antiphospholipid syndrome induction exacerbates a transgenic Alzheimer disease model on a female background. Neurobiology of Aging 2011, 32:272-279.
• [36]Kalashnikova LA, Korczyn AD, Shavit S, Rebrova O, Reshetnyak T, Chapman J: Antibodies to prothrombin in patients with Sneddon’s syndrome. Neurology 1999, 53:223-225.
• [37]Todorova M, Baleva M: Some recent insights into the prothrombogenic mechanisms of antiphospholipid antibodies. Curr Med Chem 2007, 14:811-826.
• [38]Schutt M, Kluter H, Hagedorn-Greiwe M, Fehm HL, Wiedemann GJ: Familial coexistence of primary antiphospholipid syndrome and factor VLeiden. Lupus 1998, 7:176-182.
• [39]Poka R, Vad S, Lakos G, Bereczki Z, Kiss E, Sipka S: Increased titer of anti-beta2-glycoprotein I IgG antibody among factor V Leiden carriers during oral contraceptive use. Contraception 2004, 69:27-30.
• [40]Mtiraoui N, Borgi L, Hizem S, Nsiri B, Finan RR, Gris JC, Almawi WY, Mahjoub T: Prevalence of antiphospholipid antibodies, factor V G1691A (Leiden) and prothrombin G20210A mutations in early and late recurrent pregnancy loss. Eur J Obstet Gynecol Reprod Biol 2005, 119:164-170.
• [41]Besnier R, Frances C, Ankri A, Aiach M, Piette JC: Factor V Leiden mutation in Sneddon syndrome. Lupus 2003, 12:406-408.
• [42]Dizon-Townson D, Hutchison C, Silver R, Branch DW, Ward K: The factor V Leiden mutation which predisposes to thrombosis is not common in patients with antiphospholipid syndrome. Thromb Haemost 1995, 74:1029-1031.
• [43]Pablos JL, Caliz RA, Carreira PE, Atsumi T, Serrano L, Amengual O, Santiago B, Khamashta MA, Hughes GR, Gomez-Reino JJ: Risk of thrombosis in patients with antiphospholipid antibodies and factor V Leiden mutation. J Rheumatol 1999, 26:588-590.
• [44]Rai R, Shlebak A, Cohen H, Backos M, Holmes Z, Marriott K, Regan L: Factor V Leiden and acquired activated protein C resistance among 1000 women with recurrent miscarriage. Hum Reprod 2001, 16:961-965.